Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy | Zendy

Will R. Geisen | Zendy; Justin Berger | Zendy; Chelsea Schwartz | Zendy; Abhimanyu Reddy | Zendy; Balaj Rai | Zendy; George Wadih | Zendy; Joshua Peck | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cytomegalovirus Enterocolitis secondary to experimental COVID-19 therapy

Author(s) -

Will R. Geisen,

Justin Berger,

Chelsea Schwartz,

Abhimanyu Reddy,

Balaj Rai,

George Wadih,

Joshua Peck

Publication year - 2020

Publication title -

idcases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.319

H-Index - 13

ISSN - 2214-2509

DOI - 10.1016/j.idcr.2020.e00962

Subject(s) - medicine , cytomegalovirus , covid-19 , colonoscopy , intensive care medicine , pandemic , coronavirus , enterocolitis , diarrhea , necrotizing enterocolitis , shock (circulatory) , mortality rate , etiology , immunology , pediatrics , virology , virus , viral disease , infectious disease (medical specialty) , herpesviridae , colorectal cancer , disease , cancer , outbreak

The novel coronavirus-2019 (COVID-19) has caused a global pandemic of historical proportions, infecting millions of people worldwide. Due to its high mortality rate and a paucity of clinical data, experimental therapies have been utilized with uncertain success and, unfortunately, poor outcomes. We describe a gentleman who was treated with experimental therapies and subsequently developed cytomegalovirus colitis and hypovolemic shock. Additionally, this case validates colonoscopy as a mode to rule out concurrent infectious etiologies causing diarrhea in COVID-19-positive patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research